{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T07:29:42Z","timestamp":1742801382585},"reference-count":7,"publisher":"Cambridge University Press (CUP)","issue":"4","license":[{"start":{"date-parts":[[2014,3,19]],"date-time":"2014-03-19T00:00:00Z","timestamp":1395187200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Laryngol. Otol."],"published-print":{"date-parts":[[2014,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S0022215114000401_sec1\"><jats:title>Background:<\/jats:title><jats:p>The potential efficacy of antifungal agents (e.g. Mycostatin) in treating acute attacks of M\u00e9ni\u00e8re's disease was first suggested in 1983 but few data have been published. Oral Mycostatin has been used as second-line medical treatment for intractable M\u00e9ni\u00e8re's disease at our institution for many years.<\/jats:p><\/jats:sec><jats:sec id=\"S0022215114000401_sec2\"><jats:title>Objective:<\/jats:title><jats:p>This preliminary cohort study investigated the role of oral Mycostatin in intractable M\u00e9ni\u00e8re's disease.<\/jats:p><\/jats:sec><jats:sec id=\"S0022215114000401_sec3\"><jats:title>Methods:<\/jats:title><jats:p>A retrospective review of patients with intractable M\u00e9ni\u00e8re's disease who started oral Mycostatin treatment between 2010 and 2012 was conducted.<\/jats:p><\/jats:sec><jats:sec id=\"S0022215114000401_sec4\"><jats:title>Results:<\/jats:title><jats:p>Of 256 patients presenting with vertiginous disorders, 26 had definite M\u00e9ni\u00e8re's disease and had not responded to standard first-line treatment. Following oral Mycostatin treatment, improvements were reported for vertigo (<jats:italic>n<\/jats:italic>\u00a0=\u00a08), aural fullness (<jats:italic>n<\/jats:italic>\u00a0=\u00a07), tinnitus (<jats:italic>n<\/jats:italic>\u00a0=\u00a03) and subjective hearing loss (<jats:italic>n<\/jats:italic>\u00a0=\u00a03). Half of those with symptom improvement persisted with oral Mycostatin for two years and continued to remain asymptomatic.<\/jats:p><\/jats:sec><jats:sec id=\"S0022215114000401_sec5\"><jats:title>Conclusion:<\/jats:title><jats:p>The use of oral Mycostatin to alleviate symptoms of intractable M\u00e9ni\u00e8re's disease showed promising results in this case series. Mycostatin may offer a safe and useful alternative for the management of M\u00e9ni\u00e8re's disease for patients with chronic unremitting symptoms in whom first-line treatment options have failed.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s0022215114000401","type":"journal-article","created":{"date-parts":[[2014,3,19]],"date-time":"2014-03-19T08:31:55Z","timestamp":1395217915000},"page":"379-380","source":"Crossref","is-referenced-by-count":2,"title":["Oral Mycostatin as a possible alternative treatment for intractable M\u00e9ni\u00e8re's disease: preliminary cohort study"],"prefix":"10.1017","volume":"128","author":[{"given":"A C","family":"Leong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D D","family":"Pothier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J A","family":"Rutka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2014,3,19]]},"reference":[{"key":"S0022215114000401_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0194-5998(95)70102-8"},{"key":"S0022215114000401_ref2","doi-asserted-by":"publisher","DOI":"10.1288\/00005537-197209000-00013"},{"key":"S0022215114000401_ref3","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.131.9.830"},{"key":"S0022215114000401_ref6","doi-asserted-by":"publisher","DOI":"10.1002\/lary.1977.87.11.1870"},{"key":"S0022215114000401_ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-012-0457-3"},{"key":"S0022215114000401_ref7","doi-asserted-by":"publisher","DOI":"10.1177\/019459988910000102"},{"key":"S0022215114000401_ref1","unstructured":"Nelson RA . Successful treatment of immune inner ear symptoms with nystatin: preliminary findings. Presented at the 28th Annual Scientific Meeting of the American Neurotology Society, 17 April 1993, Los Angeles, California. In: http:\/\/www.mwilliamson.com\/hearingloss.htm [13 February 2014]"}],"container-title":["The Journal of Laryngology &amp; Otology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0022215114000401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T22:04:53Z","timestamp":1555970693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0022215114000401\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,19]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0022215114000401"],"URL":"https:\/\/doi.org\/10.1017\/s0022215114000401","relation":{},"ISSN":["0022-2151","1748-5460"],"issn-type":[{"value":"0022-2151","type":"print"},{"value":"1748-5460","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,19]]}}}